Wright Center for Clinical and Translational Research, Richmond, VA.
Department of Pharmacotherapy, School of Pharmacy, Richmond, VA.
J Cardiovasc Pharmacol. 2019 Dec;74(6):528-534. doi: 10.1097/FJC.0000000000000740.
Cocaine use disorder (CUD) is a common problem in the United States and worldwide. The mechanisms by which cocaine induces acute cardiovascular toxicity are various. When systemically absorbed through inhaled or intravenous routes, cocaine induces an acute rise in the heart rate (HR) and blood pressure (BP) leading to a significant increase in the cardiac output (CO) and myocardial oxygen demand. Subjects with chronic CUD represent a special population that has experienced long-term cocaine exposure, often without showing signs of cardiovascular disease. We herein present prospectively collected data on the acute hemodynamic effects of intravenous cocaine in a cohort of nontreatment-seeking individuals with CUD without cardiovascular disease.
Baseline physiologic data were collected while participants underwent infusion of escalating doses of cocaine (10, 20, and 40 mg administered over 2 minutes) at baseline and after receiving single-blind placebo treatment. Continuous noninvasive hemodynamic monitoring was performed throughout the infusion sessions using the ccNexfin finger cuffs (Edwards Lifesciences Corp, Irvine, CA). The recorded arterial BP tracings allowed for the measurement of beat-to-beat changes in HR, BP, stroke volume, CO, and systemic vascular resistance (SVR). None of the subjects experienced a treatment-related serious adverse event. Cocaine produced significant dose-dependent increases in median HR, BP, CO, and +dP/dt (a measure of cardiac contractility) and a significant dose-dependent reduction in median SVR.
Intravenous cocaine in a cohort of otherwise healthy subjects with CUD produced dose-dependent increases in CO, largely explained by an increase in HR, accompanied by a dose-dependent decrease in SVR.
可卡因使用障碍(CUD)在美国和全球范围内都是一个常见的问题。可卡因引起急性心血管毒性的机制多种多样。当通过吸入或静脉途径全身吸收时,可卡因会导致心率(HR)和血压(BP)急性升高,从而导致心输出量(CO)和心肌氧需求显著增加。患有慢性 CUD 的受试者代表了一个特殊的人群,他们经历了长期的可卡因暴露,通常没有心血管疾病的迹象。我们在此前瞻性地收集了一组无心血管疾病的非治疗寻求的 CUD 患者静脉内可卡因急性血液动力学效应的数据。
在参与者接受可卡因(在 2 分钟内给予 10、20 和 40mg)递增剂量输注的基线和接受单盲安慰剂治疗后,收集基线生理数据。在整个输注过程中使用 ccNexfin 手指袖带(Edwards Lifesciences Corp,Irvine,CA)进行连续无创血液动力学监测。记录的动脉血压轨迹允许测量 HR、BP、每搏量、CO 和全身血管阻力(SVR)的逐拍变化。没有受试者发生与治疗相关的严重不良事件。可卡因产生了显著的剂量依赖性增加,包括 HR、BP、CO 和+dP/dt(衡量心脏收缩性的指标)中位数增加,以及 SVR 中位数显著剂量依赖性降低。
静脉内可卡因在一组其他健康的 CUD 受试者中产生了剂量依赖性的 CO 增加,这主要归因于 HR 的增加,同时 SVR 呈剂量依赖性降低。